Vera Therapeutics to Participate in the TD Cowen Immunology & Inflammation Summit
Rhea-AI Summary
Vera Therapeutics (Nasdaq: VERA) announced that its management team will present at the TD Cowen Immunology & Inflammation Summit, held virtually on November 12-13, 2025. The company presentation is scheduled for Thursday, November 13, 2025 at 1:30pm ET.
Management will also hold one-on-one investor meetings. A live webcast is available at the provided link and a replay will be accessible for 90 days via the company’s Investor Calendar.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, VERA gained 14.72%, reflecting a significant positive market reaction. Argus tracked a peak move of +16.9% during that session. Our momentum scanner triggered 29 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $247M to the company's valuation, bringing the market cap to $1.93B at that time.
Data tracked by StockTitan Argus on the day of publication.
BRISBANE, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s management team will present at the TD Cowen Immunology & Inflammation Summit, which is taking place virtually from November 12-13, 2025. The management team will also participate in one-on-one investor meetings.
Presentation Details:
Date: Thursday, November 13, 2025
Time: 1:30pm ET
Webcast: https://wsw.com/webcast/cowen185/vera/2021228
A replay of the event will be available for 90 days and can be accessed by visiting the “Investor Calendar” section of the Vera Therapeutics website.
About Vera Therapeutics
Vera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera Therapeutics’ mission is to advance treatments that target the source of disease in order to change the standard of care for patients. Vera Therapeutics’ lead product candidate is atacicept, a fusion protein self-administered at home as a subcutaneous once weekly injection that blocks both BAFF and APRIL, which stimulate B cells to produce autoantibodies contributing to certain autoimmune diseases, including IgAN and lupus nephritis. Beyond IgAN, Vera Therapeutics is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove clinically meaningful. In addition, Vera Therapeutics holds an exclusive license agreement with Stanford University for a novel, next generation fusion protein targeting BAFF and APRIL, known as VT-109, with wide therapeutic potential across the spectrum of B-cell–mediated diseases. Vera Therapeutics is also developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus, which can have devastating consequences in kidney transplant recipients. Vera Therapeutics retains all global developmental and commercial rights to atacicept, VT-109, and MAU868. For more information, please visit www.veratx.com.
For more information, please contact:
Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569
jallaire@lifesciadvisors.com
Media Contact:
Debra Charlesworth
Vera Therapeutics
415-854-8051
corporatecommunications@veratx.com
FAQ
When will Vera Therapeutics (VERA) present at the TD Cowen Immunology & Inflammation Summit?
How can investors watch the Vera Therapeutics (VERA) presentation on November 13, 2025?
Will Vera Therapeutics (VERA) meet with investors during the TD Cowen Summit?
How long will the Vera Therapeutics (VERA) webcast replay be available?
What topics will Vera Therapeutics (VERA) cover at the TD Cowen Immunology & Inflammation Summit?
Where can I find the Vera Therapeutics (VERA) presentation replay after the summit?
